Related Experiment Video
Updated: May 9, 2026
Assessing Microglial Phagocytosis of Myelin Debris in vitro Under Repeated Magnetic Stimulation
Published on: June 17, 2025
Reduction of microglial activity in a model of multiple sclerosis by dipyridamole
Scott Sloka1, Luanne M Metz, Walter Hader
1Hotchkiss Brain Institute and the Department of Clinical Neurosciences, University of Calgary, 3330 Hospital Drive, Calgary, AB T2N 4N1, Canada.
Background:
Despite extensive and persistent activation of microglia in multiple sclerosis (MS), microglia inhibitors have not yet been identified for treatment of the disorder. We sought to identify medications already in clinical use that could inhibit the activation of microglia. On the basis of the reported inhibitory effects of dipyridamole on phosphodiesterase activity that result in the production of various anti-inflammatory outcomes, we selected it for study. Dipyridamole is used clinically for secondary prevention in stroke. In this study, dipyridamole was examined using microglia in culture and in the mouse model of MS, experimental autoimmune encephalomyelitis (EAE).
Results:
We found that dipyridamole attenuated the elevation of several cytokines and chemokines in human microglia caused by Toll-like receptor stimulation. Morphological characteristics of activated microglia in culture were also normalized by dipyridamole. In mice, dipyridamole decreased the clinical severity of EAE and reduced microglial activity and other histological indices of EAE in the spinal cord.
Conclusions:
Dipyridamole is an inhibitor of microglia activation and may have a role in MS and other neurological conditions to attenuate microglial activity.
Insights
Dipyridamole, a stroke prevention drug, effectively inhibits microglia activation. This finding suggests its potential therapeutic role in multiple sclerosis (MS) and other neurological disorders.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Microglia activation is a hallmark of multiple sclerosis (MS) but lacks targeted inhibitors.
- Existing treatments do not address microglial hyperactivity.
- Dipyridamole, a drug used for stroke prevention, inhibits phosphodiesterase activity, leading to anti-inflammatory effects.
Purpose of the Study:
- To investigate dipyridamole's potential as a microglia inhibitor.
- To evaluate dipyridamole's efficacy in preclinical models of neuroinflammation.
Main Methods:
- In vitro studies using human microglia stimulated with Toll-like receptors.
- In vivo studies using the experimental autoimmune encephalomyelitis (EAE) mouse model of MS.
- Assessment of cytokine/chemokine levels, microglial morphology, clinical EAE scores, and spinal cord histology.
Main Results:
- Dipyridamole significantly reduced pro-inflammatory cytokines and chemokines in human microglia.
- Dipyridamole normalized the morphology of activated microglia in culture.
- In EAE mice, dipyridamole decreased clinical disease severity and reduced spinal cord microglial activation and inflammation.
Conclusions:
- Dipyridamole demonstrates potent inhibition of microglia activation.
- Dipyridamole holds promise as a therapeutic agent for MS and other neurological conditions characterized by microglial overactivity.
More Related Videos
09:46Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
Published on: September 21, 2021
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016